Evidence map›Paper›PMID 31159162›Full record

ArticleMolecules (Basel, Switzerland)2019

Sarconesin II, a New Antimicrobial Peptide Isolated from

Andrea Díaz-Roa, Abraham Espinoza-Culupú, Orlando Torres-García, Monamaris M Borges, Ivan N Avino, Flávio L Alves, Antonio Miranda, Manuel A Patarroyo, Pedro I da Silva, Felio J Bello

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Pep5-Cpp, a Cyclin D2-Derived Antimicrobial.Molecules (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Andrea Díaz-RoaSpecial Laboratory for Applied Toxinology (LETA), Butantan Institute, São Paulo CEP 05503-900, SP, Brazil. andreadiazroa186@gmail.com.ORCID 0000-0002-1107-0966
Abraham Espinoza-CulupúInstitute of Biomedical Sciences, University of São Paulo, São Paulo CEP 05508-900, SP, Brazil. abraham.culupu@butantan.gov.br.
Orlando Torres-GarcíaMedicine Faculty, Universidad Antonio Nariño, Bogotá 110231, Colombia. ortorres@uan.edu.co.
Monamaris M BorgesBacteriology Laboratory, Butantan Institute, São Paulo CEP 05503-900, SP, Brazil. monamaris.borges@butantan.gov.br.
Ivan N AvinoSpecial Laboratory of Cell Cycle (LECC), Butantan Institute, São Paulo CEP 05503-900, SP, Brazil. ivan.avino@butantan.gov.br.
Flávio L AlvesBiophysics Department, UNIFESP, São Paulo CEP 04023-062, Brazil. pelopes2@yahoo.com.br.ORCID 0000-0002-3874-4473
Antonio MirandaBiophysics Department, UNIFESP, São Paulo CEP 04023-062, Brazil. amiranda@unifesp.br.
Manuel A PatarroyoMolecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá 111321, Colombia. mapatarr.fidic@gmail.com.ORCID 0000-0002-4751-2500
Pedro I da SilvaSpecial Laboratory for Applied Toxinology (LETA), Butantan Institute, São Paulo CEP 05503-900, SP, Brazil. pedro.junior@butantan.gov.br.ORCID 0000-0001-6619-6489
Felio J BelloFaculty of Agricultural and Livestock Sciences, Veterinary Medicine Programme, Universidad de La Salle, Bogotá 110141, Colombia. fbgarcia5@yahoo.es.ORCID 0000-0003-1459-0278
Universidade de São Paulo · BRInstituto Butantan · BRUniversidade Federal de São Paulo · BRFundación Instituto de Inmunología de Colombia · COUniversidad Antonio Nariño · COUniversity of La Salle · CO

Funding

Brazilian National Technological and Scientific Development Council (CNPq) Grant 472744/2012-7Colombian Science, Technology, and Innovation Department (COLCIENCIAS) Call for research projects 617, ColombiaColombian Science, Technology, and Innovation Department (COLCIENCIAS) COLCIENCIAS-UAN agreement FP44842-384-2016 (Project code No. 125371250687)São Paulo Research Foundation (FAPESP) Grant 13/07467-1 to CeTICS-CEPID
6 · The paper itself

Abstract

Antibiotic resistance is at dangerous levels and increasing worldwide. The search for new antimicrobial drugs to counteract this problem is a priority for health institutions and organizations, both globally and in individual countries.

Indexed as

Amino Acid SequenceAnimalsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesBacteriaChemical PhenomenaChromatography, High Pressure LiquidDipteraDose-Response Relationship, DrugMass SpectrometryMicrobial Sensitivity TestsModels, MolecularProtein ConformationStructure-Activity RelationshipAnti-Bacterial AgentsAntimicrobial Cationic Peptidesalpha-helixantimicrobial peptideCalliphoridaedrugSarconesiopsis magellanica

Identifiers

PMID31159162
PMCPMC6600161
OpenAlexW2947025990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.